{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0012","upperLimit":"0.0017","value":"0.0014"},{"groupId":"OG001","lowerLimit":"0.0011","upperLimit":"0.0014","value":"0.0013"},{"groupId":"OG002","lowerLimit":"0.0011","upperLimit":"0.0015","value":"0.0013"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"Quantitative MRI measures Fractional Anisotropy (FA) change per month in right temporal lobe over time in each risk group will be assessed using a random effects model incorporating various covariates. Covariates to be considered include age at diagnosis, time since diagnosis and risk-arm. Differences in quantitative MRI measures of neurostructure volume and integrity between patient groups will be evaluated as a metric of structural neurotoxicity of therapy.\n\nFractional anisotropy (FA) is a scalar unitless measure that quantifies the degree of anisotropy of a diffusion process, particularly in the context of diffusion tensor imaging (DTI) used in MRI scans. FA values range from 0 to 1","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with (M0) medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"Eligible infratentorial medulloblastoma, ependymoma, and pineoblastoma patients(n=75) were included.","reportingStatus":"POSTED","timeFrame":"From baseline (month 0) to 60 months (therapy duration lasted approximately 48 weeks or 11 months)","title":"Change in Neurostructure, Especially White Matter Volume and Integrity","type":"SECONDARY","unitOfMeasure":"Change in FA per month"}